Glioblastoma
Novel gene therapy shows preliminary efficacy for glioblastoma
A novel oncolytic virus gene therapy extended survival among a small cohort of patients with high-grade glioblastoma, according to study results published in Nature.
Anti-CTLA-4 immune checkpoint inhibitor may hold promise for glioblastoma treatment
Researchers at Salk Institute for Biological Studies have achieved promising results in early studies using an anti-CTLA-4 antibody for treatment of glioblastoma, the most common and deadliest form of brain cancer.
FDA grants fast track designation to leukemia, lymphoma and endometrial cancer therapies
The FDA announced several regulatory actions.
FDA expands approval of Temodar to treat brain cancer
The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.
Partnership announces addition of novel cancer-killing biologic to glioblastoma trial
A California-based nonprofit and a biotechnology firm announced the activation of novel biologic ADI-PEG 20 in the GBM AGILE platform trial, a study that evaluates therapies for individuals with newly diagnosed or recurring glioblastoma.
FDA approves diagnostic for GI stromal tumors, seeks more data for GVHD therapy
The FDA announced several regulatory actions the past few weeks.
Glioblastoma Awareness Day: Combination provides ‘notable’ survival benefit
Today is Glioblastoma Awareness Day.
Oncolytic virus plus immunotherapy extends survival in recurrent glioblastoma
The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.
Brain Cancer Awareness Month: Vaccine confers benefit, AI identifies potential targets
May is Brain Cancer Awareness Month.
Disulfiram and copper ‘should not be recommended’ for patients with recurrent glioblastoma
The addition of disulfiram and copper to chemotherapy did not result in a significant survival benefit for patients with recurrent glioblastoma, according to data published in JAMA Network Open.